Cancer Nanotechnology

metrics 2024

Transforming Oncology with Cutting-Edge Nanotech Solutions

Introduction

Cancer Nanotechnology is a cutting-edge peer-reviewed journal dedicated to advancing the field of cancer research through innovative nanotechnology applications. Published by SPRINGER WIEN, this open-access journal, established in 2010, provides a vital platform for the dissemination of high-quality research with a focus on the intersection of nanotechnology, oncology, and biomedical engineering. With a commitment to promoting accessibility and fostering collaboration, Cancer Nanotechnology has gained impressive rankings within specialized categories, including Q2 in Biomedical Engineering and Pharmaceutical Science. The journal's rigorous selection process ensures that only the most impactful studies reach its audience, making it a must-read for researchers, professionals, and students eager to explore the latest advancements and methodologies in cancer treatment. With its scope encompassing critical topics that bridge multiple disciplines—including physical chemistry and toxicology—Cancer Nanotechnology positions itself as an influential resource for shaping the future of cancer therapies.

Metrics 2024

SCIMAGO Journal Rank0.67
Journal Impact Factor4.50
Journal Impact Factor (5 years)5.10
H-Index36
Journal IF Without Self4.50
Eigen Factor0.00
Normal Eigen Factor0.16
Influence0.77
Immediacy Index1.30
Cited Half Life3.70
Citing Half Life5.90
JCI0.82
Total Documents269
WOS Total Citations998
SCIMAGO Total Citations2055
SCIMAGO SELF Citations54
Scopus Journal Rank0.67
Cites / Document (2 Years)4.21
Cites / Document (3 Years)4.43
Cites / Document (4 Years)5.02

Metrics History

Rank 2024

Scopus

Pharmaceutical Science in Pharmacology, Toxicology and Pharmaceutics
Rank #68/183
Percentile 62.84
Quartile Q2
Physical and Theoretical Chemistry in Chemistry
Rank #75/189
Percentile 60.32
Quartile Q2
Oncology in Medicine
Rank #163/404
Percentile 59.65
Quartile Q2
Biomedical Engineering in Engineering
Rank #128/303
Percentile 57.76
Quartile Q2

IF (Web Of Science)

NANOSCIENCE & NANOTECHNOLOGY
Rank 61/140
Percentile 56.80
Quartile Q2
ONCOLOGY
Rank 78/322
Percentile 75.90
Quartile Q1

JCI (Web Of Science)

NANOSCIENCE & NANOTECHNOLOGY
Rank 50/140
Percentile 64.29
Quartile Q2
ONCOLOGY
Rank 109/322
Percentile 66.15
Quartile Q2

Quartile History

Similar Journals

Anti-Cancer Agents in Medicinal Chemistry

Advancing cancer therapeutics through innovative chemistry.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1871-5206Frequency: 10 issues/year

Anti-Cancer Agents in Medicinal Chemistry is a pivotal journal in the realm of cancer research, published by Bentham Science Publishers in the United Arab Emirates. With an ISSN of 1871-5206 and an E-ISSN of 1875-5992, this esteemed journal has been disseminating high-quality research since its inception in 2006, and is set to continue through 2024. The journal is categorized in the third quartile (Q3) across key areas including Cancer Research, Molecular Medicine, and Pharmacology, highlighting its essential role in providing valuable insights to the scientific community. Despite its open-access status being unspecified, researchers benefit from the rigorous peer-review process ensuring the publication of significant advancements. The journal ranks well within Scopus, particularly in the fields of Pharmacology and Cancer Research, which positions it as a notable resource for professionals, students, and researchers aiming to deepen their knowledge in anti-cancer strategies. Through its comprehensive scope, the journal aims to bridge the gap between medicinal chemistry and clinical applications, making it an indispensable tool for those dedicated to advancing cancer therapeutics.

BME Frontiers

Empowering Research to Transform Healthcare
Publisher: AMER ASSOC ADVANCEMENT SCIENCEISSN: Frequency: 1 issue/year

BME Frontiers, published by the American Association for the Advancement of Science, is an innovative open-access journal dedicated to the burgeoning field of Biomedical Engineering. Since its establishment in 2020, this journal has aimed to bridge the gap between cutting-edge research and practical application, promoting advancements in biomedical technologies, medical devices, and healthcare solutions. Boasting impressive rankings within Scopus—64th among 398 in Medicine (miscellaneous) and 81st among 303 in Biomedical Engineering—BME Frontiers stands out as a significant contributor to scholarly communication, offering rich insights for researchers, professionals, and students alike. With consistent publication projected through 2024, the journal serves as an essential platform for disseminating high-quality research that can drive innovation and inspire new approaches in the healthcare sector.

Cancer Research and Treatment

Leading the charge in cancer research and innovation.
Publisher: KOREAN CANCER ASSOCIATIONISSN: 1598-2998Frequency: 4 issues/year

Cancer Research and Treatment is a premier academic journal published by the Korean Cancer Association that focuses on advancing scientific knowledge and clinical practices in the fields of cancer research and oncology. With an ISSN of 1598-2998 and an E-ISSN of 2005-9256, the journal showcases cutting-edge research articles, clinical trials, and comprehensive reviews that address the multifaceted challenges in cancer treatment and management. Published in South Korea, this journal has established itself as a critical resource, evidenced by its Q1 rank in Oncology and Q2 rank in Cancer Research, reflecting its influence and stature within the academic community. The impact of research disseminated through Cancer Research and Treatment is underscored by its significant percentile rankings in Scopus, with notable positions in both the pharmaceutical and biological sectors. This journal aims to bridge the gap between laboratory research and clinical application, providing a platform for researchers, healthcare professionals, and students to enhance their understanding of cancer-related innovations and therapeutic strategies. Readers will benefit from rich content that not only discusses the latest advancements but also engages with pressing global health issues related to cancer.

International Journal of Nanomedicine

Connecting science and medicine through nanomedicine insights.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1178-2013Frequency: 1 issue/year

International Journal of Nanomedicine, published by DOVE MEDICAL PRESS LTD, is a leading open access journal dedicated to advancing the field of nanomedicine and its applications in healthcare. Since its establishment in 2006, the journal has grown significantly, now encompassing a wide array of topics including bioengineering, biomaterials, biophysics, drug discovery, and pharmaceutical sciences, and is recognized in Q1 quartiles across major categories like *Nanoscience and Nanotechnology* and *Organic Chemistry*. The journal boasts an impressive standing within the Scopus rankings, with high percentiles across various related fields, making it an invaluable resource for researchers, professionals, and students seeking to stay informed on the latest innovations and developments in nanomedicine. With its commitment to fostering an accessible and collaborative academic environment, the International Journal of Nanomedicine serves as a vital platform for disseminating transformative research that impacts scientific practice and healthcare outcomes globally.

Microfluidics and Nanofluidics

Navigating the Nexus of Physics and Chemistry
Publisher: SPRINGER HEIDELBERGISSN: 1613-4982Frequency: 1 issue/year

Microfluidics and Nanofluidics is a distinguished academic journal published by Springer Heidelberg, focusing on the rapidly evolving fields of micro and nanotechnology. With a commitment to disseminating cutting-edge research, this peer-reviewed journal aims to bridge the gap between fundamental science and practical application within Condensed Matter Physics, Materials Chemistry, and Nanoscience and Nanotechnology. It holds an influential position in its field, reflected by its Category Quartiles (Q3) and notable Scopus Rankings, including a ranking of #145 in Condensed Matter Physics. Researchers, professionals, and students will find this journal to be an invaluable resource for accessing pioneering studies, methodologies, and innovative technologies essential for advancing knowledge and applications in micro and nanofluidics. With an extensive history from 2004 to 2024, Microfluidics and Nanofluidics continues to foster discussion and collaboration within the scientific community, solidifying its role as a leading platform for scholarly communication in this dynamic discipline.

JOURNAL OF DRUG TARGETING

Connecting researchers to the forefront of drug delivery science.
Publisher: TAYLOR & FRANCIS LTDISSN: 1061-186XFrequency: 10 issues/year

JOURNAL OF DRUG TARGETING, published by Taylor & Francis Ltd, is a premier academic journal dedicated to advancing the field of pharmaceutical sciences with a strong focus on drug delivery and targeting methodologies. With an impressive impact factor and recognized as a Q1 journal in the Pharmaceutical Science category, it ranks #23 out of 183 in Pharmacology, Toxicology and Pharmaceutics, placing it within the top 13% of journals in its field. The journal provides a platform for interdisciplinary research, showcasing innovative techniques and breakthrough findings that serve to improve therapeutic efficacy through precision targeting. Although it operates under a subscription model, researchers benefit from extensive access to pivotal studies spanning from 1986 to 2024. The JOURNAL OF DRUG TARGETING aims to foster collaboration among academics, professionals, and students, making it an essential resource for those seeking to leverage the latest advancements in drug development and delivery systems for improved healthcare outcomes.

CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS

Enhancing understanding of therapeutic delivery systems.
Publisher: BEGELL HOUSE INCISSN: 0743-4863Frequency: 6 issues/year

CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS is an esteemed academic journal published by BEGELL HOUSE INC, focusing on the innovative field of drug delivery systems and therapeutic carriers. With an ISSN of 0743-4863 and E-ISSN 2162-660X, this journal serves as a pivotal resource for researchers, professionals, and students engaged in pharmaceutical sciences and pharmacology. Spanning from 1984 to 2024, it has sustained its relevance in an evolving landscape, holding a commendable Q2 ranking in both Medicine (miscellaneous) and Pharmaceutical Science, as well as a Q3 ranking in Pharmacology for 2023. The journal is well-regarded for its critical and comprehensive reviews that enhance understanding and drive advancements in therapeutic applications. Access options are variable, providing insights into contemporary practices and innovations that shape drug delivery strategies. With a strong emphasis on interdisciplinary approaches, CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS not only fosters scholarly dialogue but also propels forward the critical field of therapeutic delivery, making it a valuable asset for anyone looking to deepen their knowledge and influence within this dynamic area of study.

Nanomedicine

Advancing the Future of Medicine through Nanotechnology
Publisher: FUTURE MEDICINE LTDISSN: 1743-5889Frequency: 30 issues/year

Nanomedicine, published by Future Medicine Ltd, is a premier academic journal dedicated to the rapidly evolving field of nanotechnology in medicine. With an emphasis on innovative research and applications, this journal encompasses a broad spectrum of topics including bioengineering, biomedical engineering, and nanoscience, among others. Featuring an impressive Q1 ranking in Development and multiple Q2 rankings across significant categories, it serves as a pivotal resource for researchers and professionals aiming to stay at the forefront of advancements in these disciplines. While the journal is not open access, it is accessible through various institutional subscriptions, ensuring wide dissemination of cutting-edge findings. Notably, it has achieved substantial impact within the scientific community, indicated by its high rankings in Scopus and overall commitment to enhancing the understanding and application of nanomedicine. This journal is a vital conduit for fostering collaborations and innovations that transcend traditional medical paradigms.

Journal of Reports in Pharmaceutical Sciences

Empowering Researchers with Cutting-Edge Findings.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2322-1232Frequency: 2 issues/year

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

Biomaterials Science

Uniting academia and industry to revolutionize biomaterials science.
Publisher: ROYAL SOC CHEMISTRYISSN: 2047-4830Frequency: 24 issues/year

Biomaterials Science is a premier journal published by the Royal Society of Chemistry that serves as a leading platform for researchers and professionals in the fields of Biomedical Engineering and Materials Science. With an impressive impact factor bolstered by its Q1 quartile ranking in both disciplines, this journal has positioned itself at the forefront of cutting-edge research, showcasing innovative materials and applications that drive advancements in healthcare and technology. Since its inception in 2013, Biomaterials Science has been committed to disseminating high-quality, peer-reviewed articles that promote scientific knowledge and collaboration among academia and industry. With a global readership and a focus on open access, researchers are encouraged to share their findings to facilitate the development of transformative biomaterials and their applications. Join a vibrant community of scholars as we explore the future of biomaterials through this esteemed publication, enhancing both scientific inquiry and practical application.